Skip to content
OpenCapital
Get started

Halozyme Therapeutics HALO Trading assets

Trading assets at other companies

Viatris logo
ViatrisVTRS
——
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE
——

Other financials

Income statement

See full
Revenue$376.7M+42.2%
Gross profit$297.5M+37.4%
Operating income$184.5M+30.4%
Net income$150.0M+27.1%
EPS (diluted)$1.22+31.2%

Balance sheet

See full
Cash & equivalents$312.0M+76.9%
Total debt$2.2B+41.7%
Total equity$219.6M-54.5%
Total assets$2.7B+21.7%

Cash flow

See full
Operating cash flow$180.1M+16.8%
CapEx$3.7M+294%
Free cash flow$176.3M+15.0%

Valuation

See full
Market cap$8.13B-2.9%
Enterprise value$10B+3.0%
P/E13.4×-3.8×
P/S5.4×-2.3×

Profitability

See full
Gross margin82.8%-0.7pp
Operating margin59.3%+9.0pp
Net margin47.9%+6.5pp
FCF margin44.3%-1.5pp

Returns & leverage

See full
Return on equity124.5%+12.7pp
Debt / equity9.9×+6.7×
Current ratio2.8×-5.6×

Where this comes from

Reported directly by Halozyme Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue.

The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Halozyme Therapeutics's trading assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Halozyme Therapeutics's trading assets?
Halozyme Therapeutics (HALO) reported trading assets of $8.87M in Q1 2026.
How has Halozyme Therapeutics's trading assets changed year-over-year?
Halozyme Therapeutics's trading assets decreased by 98.0% year-over-year, from $440.89M to $8.87M.
What is the long-term trend for Halozyme Therapeutics's trading assets?
Over 5 years (2020 to 2025), Halozyme Therapeutics's trading assets has grown at a -47.2% compound annual growth rate (CAGR), from $220.31M to $9M.
What does trading assets mean?
Securities and other financial instruments held for short-term trading purposes, measured at fair value with changes flowing through the income statement.